CYTOTOXIC T LYMPHOCYTE
\sˌa͡ɪtətˈɒksɪk tˈiː lˈɪmfəsˌa͡ɪt], \sˌaɪtətˈɒksɪk tˈiː lˈɪmfəsˌaɪt], \s_ˌaɪ_t_ə_t_ˈɒ_k_s_ɪ_k t_ˈiː l_ˈɪ_m_f_ə_s_ˌaɪ_t]\
Sort: Oldest first
-
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from natural killer cells (KILLER CELLS, NATURAL) and from KILLER CELLS mediating antibody-dependent cell cytotoxicity. There are two effector phenotypes: TC1 and TC2.
By DataStellar Co., Ltd
Word of the day
Proto Oncogene Proteins c erbB 2
- cell surface protein-tyrosine kinase that is found to be overexpressed in significant number adenocarcinomas. It has extensive homology can heterodimerize EGF EPIDERMAL GROWTH FACTOR), 3 receptor (RECEPTOR, 3) and the 4 receptor. Activation of erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB family members. EC 2.7.11.-.